Drug intelligence / Profile preview

1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Development stage: Unknown
Lead developer: Biokin Pharmaceutical
Modality: Small Molecules

Overview

A small molecule belonging to the class of pyrazolo[3,4-d]pyrimidines. It is a highly potent and specific inhibitor of v-Src tyrosine kinase. This compound is used in research as a tool for studying cellular signaling pathways involving Src family kinases. It has not been approved for any clinical use and remains experimental in nature[2][5][6].

Other names: 1-(tert-butyl)-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amineBLD Pharmatech BL3H99C597CAsc-206805 (Santa Cruz Biotechnology catalog number)PA2706976 (Pharmaffiliates catalog number)

Targets

SRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.

Explore the full profile